Study Participants Wanted

Note: Only studies being conducted by the UMass Department of Psychiatry will be listed here. No other entries accepted.

Members of the department wishing to submit information like this should use the format below, include a subject line of “Study Participants Wanted,” and email it to psychiatrycommunications@umassmed.edu.


ESKETINTRD3001 Study

We are currently enrolling participants in a clinical research study to look at the effectiveness and safety of an investigational medication (given as a nasal spray) in patients with depression who have not responded to prior treatment with an antidepressant and currently taking a different antidepressant.

Participants must:

  • be 18 to 64 years of age
  • have been diagnosed with depression
  • be experiencing current symptoms of depression despite taking antidepressant medications
  • have not responded to prior treatment with an antidepressant and currently taking a different antidepressant
  • must be comfortable with using a nasal spray
  • not be pregnant or have plans to become pregnant

Subjects will receive study drug and study-related care at no cost. Study participation will last up to 35 weeks. Compensation for time and travel will be provided for qualified participants.

Contact Chelsea Kosma @ 508-856-5312

Docket # H-00011026


The Depression Relapse Trial

Individuals that are currently suffering from depression are invited to participate in a research study to determine the effectiveness and safety of vortioxetine in preventing relapse in depression for those subjects who respond to treatment with vortioxetine. Study participation will last up to 55 weeks and subjects will receive the study drug vortioxetine.

Participants must be:

  • 18 to 75 years of age
  • suffering from recurrent Major Depressive Disorder
  • experiencing current symptoms of depression
  • not be pregnant or have plans to become pregnant

Subjects will receive study drug and study-related care at no cost. Compensation provided.

Contact Michelangela Yusif @ 774-455-4136

Docket # H-00007086


Investigational Drug Study for Adolescents with Schizophrenia

What are we studying?
The purpose of the study is to evaluate whether NaBen (Sodium Benzoate) is an effective add-on treatment for adolescents with schizophrenia

Who can participate?
Adolescents between 12 and 17 years of age who have a diagnosis schizophrenia. Participants need to be on a stable antipsychotic treatment for their schizophrenia and still be experiencing residual symptoms.

How will participants be compensated?
Compensation will be provided for time and travel.

For more information, contact CANDI at (774) 455-4100

Docket # H00005591 


Transition-age Youth Psychotherapy Experiences (TYPE) Study
UMass Medical School Transitions RTC Research Study for Young Adults (Ages 18-25)

The UMass Transitions Research and Training Center (RTC) is currently recruiting for a research study to better understand the experiences of young adults who are participating in outpatient psychotherapy treatment.

We are seeking:
Young adults between the ages of 18-25 who have a self-identified mental health condition and who are beginning outpatient psychotherapy or have been involved in outpatient psychotherapy for less than one year.

Participation:

  • Two interviews scheduled two months apart. Interviews will last roughly 1 hour and will include a web survey and qualitative portion.
  • Interviews will take place over the phone, or at a location of convenience (for participants located within 30 miles of Worcester, MA).
  • Participants will receive a $25 gift card for each interview completed. Young adults will be compensated up to $50 for their involvement in this study.

Please email, call, text, or visit the TYPE study webpage to learn more about the study and have all your questions answered:

Emma Pici-D’Ottavio
Call or text:774-437-2124
Email: Emma.PiciDOttavio@UMassMed.edu
Study webpage: http://www.voices4hope.net/type-study.html

IRB# H00007759


 

Outpatient Couple Therapy for Service Members and Veterans with Alcohol-Related Concerns

The Alcohol Behavioral Couple Therapy Military treatment research program is specifically designed to help service members or veterans and their partners to learn skills that will help to reduce drinking and to improve relationship functioning.

The program will include a thorough assessment, 15 weekly outpatient sessions with a spouse, partner or family member (free of charge), and a follow-up session.  Compensation will be provided for the intake and follow-up sessions.

Below are the major inclusion criteria:

  • Be a service member or veteran of the U.S. Military (all branches welcome including National Guard and Reserves)
  • Have a drinking habit you want to change
  • Be 18 or older
  • Have a significant other who can attend sessions with you (spouse, dating partner, family member)

For more information, please contact Rachel Rosen (508-856-8745) or Dr. Beth Epstein (732-995-7315).

IRB# H-3823


The Early Treatment Study


The goal of this study is to help understand if the experimental drug paliperidone palmitate or oral antipsychotic medication is better at preventing a worsening of symptoms of schizophrenia or schizophreniform disorder. We seek men and women ages 18-35 that have a clinical diagnosis of psychosis within the last 2 years. Those who qualify will receive study-related medical exams, and lab tests at no charge.

You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Funding Source: Janssen Scientific Affairs, LLC
IRB Docket # H00010209


A Psychotic Disorders Program Research Study

Exenatide weekly injection as an adjunctive treatment in patients with schizophrenia

Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking?

If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months).

You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Funding Source: Stanley Medical Research Institute
IRB Docket# H00004119


ADHD Study

Men aged 14 – 24.

Participants must be diagnosed with ADHD and be right-handed.

Participants will be asked to fill out surveys and undergo a non-invasive MRI scan. No medication is given for this study.

Compensation will be provided for time and travel.
Contact: 508-856-8185 or email CCNI.Research@umassmed.edu.

Docket H-14119